Research Report on China’s Dabigatran Etexilate Market, 2021-2025

$2,600$3,900

According to CRI’s market research, the sales value of dabigatran etexilate in China declined to approximately CNY329 million (USD50.6 million) in 2020 due to COVID-19.

Clear

Description

Dabigatran Etexilate is an oral anticoagulant drug used for the prevention of thrombus and embolus formation after major orthopedic surgery (hip or knee replacement) and for the prevention of stroke in people with non-valvular atrial fibrillation and other embolisms of the body circulation.

Dabigatran etexilate is a precursor drug of dabigatran that is enzymatically hydrolyzed in vivo to the coagulant-active dabigatran, which exerts its anticoagulant effect through direct inhibition of thrombin. Dabigatran etexilate mesylate capsules, originally developed by Boehringer Ingelheim under the trade name of Pradaxa®, were approved for marketing by EMA in March 2008 and then approved by FDA in 2010. After the launch, its sales value peaked at USD1.60 billion in 2013. The sales value then started to decrease due to the launch of other competitive anticoagulants like rivaroxaban and apixaban.

In March 2013, Dabigatran etexilate capsules were approved in China for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, under the trade name of Taibiquan® with the specifications of 110 mg/capsule and 150 mg/capsule. In 2017, Dabigatran etexilate immediate-release formulation for oral use has been included in the Category B drugs in the latest China National Reimbursement Drug List. In March 2020, Chia Tai Tianqing’s generic dabigatran etexilate capsules were approved by the NMPA for marketing in China, followed by Jiangsu Hansoh Pharmaceutical and Chengdu Easton Bio Pharmaceuticals in early 2021. And It is expected that, from 2021 to 2025, more generic dabigatran etexilate drugs will be approved.

According to CRI’s market research, the sales value of dabigatran etexilate in China declined to approximately CNY329 million (USD50.6 million) in 2020 due to COVID-19. And China’s dabigatran etexilate market was entirely dominated by Boehringer Ingelheim International GmbH before 2020. Despite the launch of Chia Tai Tianqing’s dabigatran etexilate in 2020, Boehringer Ingelheim International GmbH still held more than 99% share of the dabigatran etexilate market in China in terms of sales value. It is expected that Boehringer Ingelheim International GmbH’s share of China’s dabigatran etexilate market will decline for more generic products will become available.

 

Topics Covered:

  • Impact of COVID-19 on China’s Dabigatran Etexilate Market
  • Development Environment of Dabigatran Etexilate in China
  • Sales Volume of Dabigatran Etexilate in China
  • Sales Volume and Value of Dabigatran Etexilate in China by Region
  • Major Dabigatran Etexilate Manufacturers in China and Their Market Shares
  • Sales Price of Dabigatran Etexilate in China
  • Prospects of China’s Dabigatran Etexilate Market, 2021-2025

Additional information

Publisher

Date Published

Pages

Charts

Format

Table of Contents

Table of Contents

1 Relevant Concepts of Dabigatran Etexilate

1.1 Indications of Dabigatran Etexilate

1.2 Development of China’s Dabigatran Etexilate Market

1.3 Governmental Approval of Dabigatran Etexilate in China

1.4 The Impact of COVID-19 on China’s Dabigatran Etexilate Market

 

2 Sales of Dabigatran Etexilate in China, 2016-2020

2.1 Sales Value

2.1.1 Sales Value in China

2.1.2 Sales Value in China by Region

2.2 Sales Volume

2.2.1 Sales Volume in China

2.2.2 Sales Volume in China by Region

2.3 Sales of Dabigatran Etexilate in China by Dosage Form, 2016-2020

2.3.1 Capsules

2.3.2 Other Dosage Forms

 

3 Analysis of Major Dabigatran Etexilate Manufacturers in China, 2020

3.1 Analysis of Market Share

3.1.1 Market Share of Manufacturers by Sales Value

3.1.2 Market Share of Manufacturers by Sales Volume

3.2 Boehringer Ingelheim International GmbH

3.2.1 Company Profile

3.2.2 Sales of Dabigatran Etexilate in China

3.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

3.3.1 Company Profile

3.3.2 Sales of Dabigatran Etexilate in China

 

4 Sales Price of Dabigatran Etexilate of Different Companies in China, 2020-2021

4.1 Boehringer Ingelheim International GmbH (Pradaxa®)

4.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Anershun®)

 

5 Prospects of China’s Dabigatran Etexilate Market, 2021-2025

5.1 Influencing Factors for the Market Development

5.1.1 The Impact of COVID-19 on the Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

 

List of Charts

  • Chart Patent Information of Dabigatran Etexilate in China
  • Chart Sales Value of Dabigatran Etexilate in China, 2016-2020
  • Chart Sales Volume of Dabigatran Etexilate in China, 2016-2020
  • Chart Sales of Dabigatran Etexilate Tablets in China, 2016-2020
  • Chart Sales Volume of Dabigatran Etexilate in China by Region, 2016-2020
  • Chart Sales Value of Dabigatran Etexilate in China by Region, 2016-2020
  • Chart Market Share of Dabigatran Etexilate Manufacturers in China by Sales Value, 2016-2020
  • Chart Sales Value and Volume of Dabigatran Etexilate (of Boehringer Ingelheim International GmbH) in China, 2016-2020
  • Chart Sales Value and Volume of Dabigatran Etexilate (of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.) in China, 2016-2020
  • Chart Sales Price of Pradaxa (Dabigatran Etexilate of Boehringer Ingelheim International GmbH) in China by Region, 2020
  • Chart Sales Price of Anershun (Dabigatran Etexilate of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.) in China by Region, 2020
  • Chart Forecast on Sales Value of Dabigatran Etexilate in China, 2021-2025
  • Chart Forecast on Sales Volume of Dabigatran Etexilate in China, 2021-2025
RSS
Follow by Email